Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Overview: Gilead is a biopharmaceutical company focused on HIV, viral hepatitis, cancer, and inflammation. The company operates in over 35 countries with headquarters in Foster City, California. In 2024, the company completed the acquisition of CymaBay Therapeutics, Inc. for approximately $3.9 billion net cash, adding the investigational candidate seladelpar (Livdelzi) to its portfolio. Livdelzi received FDA accelerated approval in August 2024 for the treatment of primary biliary cholangitis (PBC).
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $28,754 | $27,116 | +6% |
| Net Income Attributable to Gilead | $480 | $5,665 | -92% |
| Diluted EPS | $0.38 | $4.50 | -92% |
| Product Gross Margin | 78.2% | 75.9% | +230 bps |
| Operating Cash Flow | $10,828 | $8,006 | +35% |
| Cash and Cash Equivalents (Year End) | $9,991 | $6,085 | N/A |
| Total Debt (Net) | $26,710 | $24,987 | N/A |
Revenue Drivers: Total revenues increased 6% primarily due to higher sales in HIV (up 8%), Oncology (up 12%), and Liver Disease (up 9%), partially offset by a decline in Veklury sales (down 18%) due to decreased COVID-19 hospitalization rates.
Material Changes vs. Prior Period
- Significant Impairment Charges: Net income declined sharply due to a pre-tax in-process research and development (IPR&D) impairment charge of $4.2 billion related to Trodelvy (sacituzumab govitecan-hziy) assets for non-small cell lung cancer (NSCLC). This followed the failure of the Phase 3 EVOKE-01 study to meet its primary endpoint and a strategic decision to discontinue the second-line NSCLC program.
- Acquisition Costs: Acquired IPR&D expenses increased to $4.7 billion (from $1.2 billion in 2023), driven primarily by the $3.8 billion CymaBay acquisition and a $320 million payment to extinguish future royalty obligations for seladelpar.
- Product Performance:
- Biktarvy: Sales increased 13% to $13.4 billion, driven by higher demand and patients switching from other Gilead HIV products.
- Trodelvy: Sales increased 24% to $1.3 billion despite the impairment, driven by higher demand across all regions.
- Veklury: Sales decreased 18% to $1.8 billion.
- Debt Activity: In November 2024, the company issued $3.5 billion in new senior unsecured notes. In February 2025 (subsequent to year-end), the company repaid $1.75 billion of senior notes due in February 2025.
Guidance, Outlook, and Risks
2025 Outlook: Management expects continued demand-led volume growth in 2025, bolstered by the HIV business. However, this growth is expected to be offset by:
- Increased payment obligations under the Inflation Reduction Act (IRA) Medicare Part D discount program.
- Decreased Veklury sales reflecting lower COVID-19 rates.
- Impact of a strengthening U.S. dollar against major foreign currencies.
Key Risks and Contingencies:
- Regulatory and Clinical: The company voluntarily withdrew the U.S. accelerated approval for Trodelvy in urothelial cancer following the TROPiCS-04 trial results. Future approvals for lenacapavir (HIV prevention) are pending.
- Legal Proceedings: The company has accrued approximately $200 million for a potential settlement with the U.S. Attorney's Office regarding promotional speaker programs. Significant antitrust litigation regarding HIV drugs remains pending, though a settlement was reached in January 2025 regarding PrEP patent litigation.
- Patent Expirations: Key products face patent expirations, including Genvoya (2029 in U.S.), Biktarvy (2033 in U.S.), and Epclusa (2033 in U.S.). Settlements with generic manufacturers have been reached for Symtuza and Genvoya, with generic entry dates set for the future.
- IRA Impact: The Inflation Reduction Act is expected to increase rebate obligations and limit pricing power, negatively impacting profitability.
Investor Verification Checklist
- IPR&D Impairment Sustainability: Verify the remaining fair value of the Trodelvy NSCLC asset ($1.8 billion) and the likelihood of further impairments if first-line trials fail.
- CymaBay Integration: Assess the commercial launch trajectory and reimbursement status of Livdelzi (seladelpar) for PBC to determine if it can offset the acquisition cost.
- HIV Portfolio Durability: Monitor Biktarvy sales trends against emerging long-acting therapies and potential generic competition for older HIV products.
- Legal Accruals: Track the status of the $200 million accrual for the Southern District of New York investigation and the outcome of the HIV antitrust appeal.
- IRA Financial Impact: Quantify the specific impact of the Medicare Part D discount program changes on 2025 net product sales and margins.